Monday, June 18, 2018 -- The vaccine has brought about an 86% reduction in cancer-causing infection, a study has found.
Wednesday, June 20, 2018 -- Missak HaigentzResearchers at Atlantic HPV Center at Leonard B. Kahn Head and Neck Cancer Institute will study immunotherapy combinations in a cohort of patients with HPV-associated head and neck cancers.Missak Haigentz, MD, chief of hematology and oncology at Morristown Medical Center and medical director of Atlantic Hematology and Oncology of Atlantic Medical Group at Carol G. Simon Cancer Center, and colleagues will conduct a phase 1b/phase 2a study that will assess an experimental HPV vaccine and treatment with the PD-L1 inhibitor durvalumab (Imfinzi; AstraZeneca).The rationale behind the
Wednesday, June 20, 2018 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for GARDASIL ® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), the company’s 9-valent HPV vaccine. Read more..
Thursday, June 21, 2018 -- Findings based on large survey of parents to assess best, worst reasons for vaccination